Skip to content

Hypotension Prediction With HPI Algorithm During Decessed-donor Kidney Transplant (HPI2022)

Hypotension Prediction With HPI Algorithm During Decessed-donor Kidney Transplant: an Explorative, Monocentric, RCT

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05394896
Acronym
HPI2022
Enrollment
46
Registered
2022-05-27
Start date
2022-11-01
Completion date
2024-01-31
Last updated
2023-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension During Surgery, Kidney Transplant; Complications

Keywords

HPI

Brief summary

HPI monitoring and the adoption of therapeutic interventions before hypotension occurs should be ensure a shorter time of intra-operative hypotension (MAP \< 65 mmHg) during deceased-donor kidney transplant surgery. The control group is represented by patients undergoing the same surgical procedure with hemodynamic monitoring with invasive blood pressure monitoring which represents the gold standard for this surgery. HPI monitoring has not yet been investigated during this surgery.

Interventions

DEVICEACUMEN (Edwards Lifesciences, Irvine, USA)

ACUMEN sensor generates HPI index which should predict hypotension. Based on HPI index, Eadyn and dP/dTmax values anaesthesia should somministrate liquid or drugs to prevent hypotension.

DEVICEInvasive Blood Pressure

Invasive Blood Pressure permits continue monitoring of blood pressure (routine standard for kidney transplant surgery)

Sponsors

IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* First single or double kidney transplant from a cadaveric donor; * ASA Class III-IV; * Signature of informed consent.

Exclusion criteria

* Patient with atrial fibrillation rhythm or high frequency tachyarrhythmias; * Severe valvulopathies; * Combined single/double kidney-liver-transplant; * Patients in whom the need for monitoring would still be expected advanced, invasive or minimally invasive hemodynamic, regardless of the allocation to the study group; * Inclusion in another study.

Design outcomes

Primary

MeasureTime frameDescription
Intra-operative hypotension timeFrom 20 minutes after anaesthesia induction to the end of surgery (intra-operative)Hypotension (MAP \< 65 mmHg) time relative to the range from 20 minutes after induction to the end of surgery

Secondary

MeasureTime frameDescription
Intra-operative severe hypotension timeFrom 20 minutes after anaesthesia induction to the end of surgery (intra-operative)Severe hypotension (MAP \< 50 mmHg) time relative to the range from 20 minutes after induction to the end of surgery
Major Adverse Cardiovascular Events (MACE)First 5 post-operative days after surgery (post-operative)Number of major cardiovascular complications (MACE) within the first five days after kidney transplantation (for MACE the composite endpoint of heart attack is considered heart failure, heart failure or presumed cardiac death)
Hospital mortalityFirst 30 post-operative days after surgery (post-operative)Number of patient died in the first 30 days after surgery
Intensive Care Unit Length of StayFirst 30 post-operative days after surgery (post-operative)Number of hours of ICU admission
Post-operative hypotension timeFrom the end of surgery to the first 12 hours after surgery (post-operative)Hypotension (MAP \< 65 mmHg) time relative to the range from the end of surgery to the first 12 hours after surgery
Delayed Graft Function (DGF)First 7 post-operative days (post-operative)Need for hemodialysis in first 7 postoperative days
Graft survival30 days after transplantation
Post-operative deliriumFirst 5 post-operative daysCAM-ICU positive (asses one time for a day in the first 5 postoperative days)
Hospital Length of StayFirst 30 post-operative days after surgery (post-operative)Number of days before hospital discharge

Countries

Italy

Contacts

Primary ContactAntonio Siniscalchi, MD
antonio.siniscalchi@aosp.bo.it+390512143131
Backup ContactLorenzo Querci, MD
lorenzo.querci@studio.unibo.it+393933980223

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026